AYTU BIOPHARMA, INC Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
AYTU BIOPHARMA, INC (AYTU) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 2.06 million shares for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2025-05-14
- AYTU BIOPHARMA, INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 2.06M shares.
- AYTU BIOPHARMA, INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-12-31 was 2.34M shares.
- AYTU BIOPHARMA, INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-09-30 was 3.03M shares.
- AYTU BIOPHARMA, INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-03-31 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2025-03-31 | 2.06M shares 10-Q · filed 2025-05-14 | 2.48M shares 10-Q · filed 2025-05-14 | |
| 2024-12-31 | 2.34M shares 10-Q · filed 2025-02-12 | 2.67M shares 10-Q · filed 2025-02-12 | |
| 2024-09-30 | 3.03M shares 10-Q · filed 2024-11-13 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | 0.00 shares 10-Q · filed 2025-05-14 | |
| 2023-12-31 | 0.00 shares 10-Q · filed 2025-02-12 | 0.00 shares 10-Q · filed 2025-02-12 | |
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |